Hexvix (Hexaminolevulinate)

Hexvix is indicated for the detection of bladder cancer during cystoscopic examination. It assists in identifying carcinoma in situ and papillary tumors that may be difficult to see under white light.

• Visualization of flat carcinoma in situ lesions.
• Detection of small papillary tumors (Ta, T1) during blue‑light cystoscopy.
• Complementary use with standard white‑light cystoscopy to improve diagnostic yield.
• Guidance for targeted biopsy or resection of suspicious areas.
• Assessment of tumor recurrence after intravesical therapy in follow‑up protocols.

• Hexaminolevulinate is a prodrug that enters urothelial cells and is metabolized in the heme biosynthetic pathway to protoporphyrin IX. The accumulated porphyrin preferentially concentrates in malignant cells because of altered enzymatic activity, and it emits red fluorescence when excited by blue light (approximately 405 nm). This fluorescence highlights cancerous tissue, allowing clinicians to differentiate it from normal bladder mucosa during photodynamic diagnosis.

Adverse reactions to Hexvix are generally related to the intravesical administration and the photosensitizing properties of hexaminolevulinate.

Common

• Mild bladder irritation or dysuria occurring during or shortly after instillation.
• Transient hematuria or pink‑tinged urine that resolves within 24 hours.
• Low‑grade urinary frequency or urgency without fever.
• Minor abdominal discomfort or suprapubic pressure.

Serious

• Severe allergic reaction such as anaphylaxis or angioedema requiring emergency care.
• Persistent or worsening hematuria that does not resolve and needs medical evaluation.
• Acute urinary retention that may necessitate catheterization.
• Significant bladder wall inflammation (cystitis) accompanied by fever or systemic symptoms.

Before using Hexvix, clinicians should consider several precautionary measures to minimize risks and ensure accurate diagnostic results.

• Verify that the patient has no known hypersensitivity to hexaminolevulinate or similar porphyrin compounds.
• Ensure the bladder is adequately emptied and free of active infection prior to instillation.
• Avoid exposure to strong ambient light for the recommended period after administration to reduce photosensitivity risk.
• Use the product only in a controlled clinical setting with appropriate blue‑light cystoscopy equipment.
• Document any prior bladder surgeries or radiation therapy, as these may affect fluorescence interpretation.
• Monitor patients for urinary symptoms during the observation period after the procedure.
• Pregnant or nursing patients should be evaluated carefully, as safety data are limited.

Hexvix may interact with other agents that influence photosensitivity or urinary tract conditions.

Avoid

• Concurrent use of systemic photosensitizing drugs (e.g., porfimer sodium, aminolevulinic acid) that could amplify fluorescence or cause adverse skin reactions.
• Administration of intravesical chemotherapy agents immediately before or after Hexvix without an appropriate washout period.

Use with caution

• Anticoagulant or antiplatelet therapy, which may increase the risk of hematuria after instillation.
• Agents that irritate the bladder mucosa (e.g., certain antibiotics or intravesical agents) as they may confound fluorescence interpretation.
• Patients receiving phototherapy or intense UV exposure; advise protection measures.